BusinessGenmab Revenue Rises 22% as Nine-Month Net Profit FallsBy Helena WardNov 6, 2026, 4:35 AM UTC
HealthGenmab’s Cancer Combination Meets Both Primary Endpoints in Phase 3 TrialBy Naomi CalderOct 29, 2026, 12:09 AM UTC
HealthGenmab Reports Tumor Responses With Experimental Colorectal Cancer CombinationBy Naomi CalderOct 25, 2026, 11:21 AM UTC
HealthGenmab and Incyte Plan Phase 1/2 Trial for KRAS G12D Colorectal CancerBy Naomi CalderOct 24, 2026, 2:02 PM UTC